Peer Reviewed Journal Articles
The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG, Burke HB, Wheeler TM, Chung LWK, Bookstein R, Pretlow TG, et al. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem Suppl 1994;19:283-89.